# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis

> **NCT01094093** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 73 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** AMG 139

## Key facts

- **NCT ID:** NCT01094093
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-11
- **Primary completion:** 2011-07-26
- **Final completion:** 2011-07-26
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01094093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01094093, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01094093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*